Somatic TP53

This page covers the tumour-acquired TP53 layer.

These are the TP53 changes that develop inside the cancer itself. They are not inherited, and they are the findings that usually matter most when the question is about tumour behaviour, resistance, or response to a specific strategy.

What somatic TP53 means

A somatic TP53 result reflects mutations found in the tumour or in tumour-derived DNA.

This is the most common TP53 conversation in oncology because somatic TP53 alterations are found in a very large share of cancers.

These findings can help explain:

• why a tumour behaves aggressively

• why resistance emerges

• why some drugs or adjunctive ideas make more sense than others

• why the same "TP53 mutation" label can mean very different things in different people

The most important rule

The words "TP53 mutation" are not enough.

You need the specific variant and the mutation class.

That determines whether:

• a full-length mutant protein is accumulating

• some function remains

• the protein is absent altogether

• the finding is likely targetable in any meaningful way

Use TP53 Mutation Types Reference when you have a variant code such as p.R175H, p.R248Q, p.P128fs, or a splice-site notation.

What tests may already contain the answer

Many people already have somatic TP53 information in existing records.

Common sources include:

• tumour NGS panels

• broad genomic profiling reports

• liquid-biopsy reports

• pathology reports using p53 immunohistochemistry

Useful examples include:

• FoundationOne CDx

• Guardant360 CDx

• FoundationOne Liquid CDx

• p53 immunohistochemistry

Tissue, liquid biopsy, and IHC are not interchangeable

Tumour tissue profiling

This is often the clearest direct view of what the cancer cells contain.

It is especially useful when a biopsy or surgical specimen is already available.

Liquid biopsy

This can detect circulating tumour DNA without a fresh tissue biopsy.

It is useful, but interpretation needs care.

p53 immunohistochemistry

This is not the same as sequencing, but it can still be very informative.

Patterns such as:

• diffuse overexpression

• complete null staining

• aberrant cytoplasmic staining

can strongly suggest an underlying TP53 abnormality even when full NGS is not available.

Why somatic TP53 matters clinically

Somatic TP53 can influence how people think about:

• treatment resistance

• likely tumour biology

• prognosis in some settings

• clinical-trial eligibility

• mechanism-based adjunctive ideas

It is also the report that directly informs questions like:

• Does the tumour still have functional p53?

• Is there a stable harmful mutant protein to clear?

• Is the tumour actually p53-null?

Those distinctions feed directly into:

• Fenbendazole and TP53

• Andrographis and Mutant p53

• NAC in p53-Mutant Cancers

Somatic and germline results can coexist

Some people have:

• no germline TP53 issue, but a somatic TP53-mutant tumour

• a germline TP53 pathogenic variant, plus a tumour that later lost the remaining good copy

That is why the germline and somatic pages need to be read together when both questions are on the table.

What to mine first

Before assuming no somatic data exists, check for:

• a variant table listing TP53 in any tumour NGS report

• liquid-biopsy reports with TP53 and variant allele frequency

• pathology wording such as p53 null, p53 overexpression, or aberrant p53 staining

Many people already have enough information to at least identify the mutation class.

The practical takeaway

Somatic TP53 testing is the layer that most directly describes what the tumour is doing now.

It does not replace germline testing. But when the question is about tumour behaviour, treatment resistance, or mutation-specific strategy, somatic testing is usually the decisive layer.

Where to go next

• Use TP53 Mutation Types Reference to decode the actual variant.

• Use Fenbendazole and TP53 for the p53-dependent fenbendazole question.

• Use Andrographis and Mutant p53 when the issue is a stable gain-of-function mutant protein.